39.86
0.85%
-0.2801
前日終値:
$40.14
開ける:
$40.18
24時間の取引高:
497.39K
Relative Volume:
0.43
時価総額:
$7.38B
収益:
$455.99M
当期純損益:
$-285.01M
株価収益率:
-12.23
EPS:
-3.26
ネットキャッシュフロー:
$-164.61M
1週間 パフォーマンス:
-0.23%
1か月 パフォーマンス:
-8.40%
6か月 パフォーマンス:
-7.36%
1年 パフォーマンス:
-30.48%
Legend Biotech Corp Adr Stock (LEGN) Company Profile
LEGN を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
LEGN | 39.85 | 7.38B | 455.99M | -285.01M | -164.61M | -3.26 |
VRTX | 448.21 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 746.51 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 590.80 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 249.20 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 103.85 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Legend Biotech Corp Adr Stock (LEGN) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2023-12-19 | 開始されました | Scotiabank | Sector Perform |
2023-11-06 | 開始されました | Goldman | Buy |
2023-05-25 | 開始されました | William Blair | Mkt Perform |
2023-05-22 | 開始されました | Daiwa Securities | Buy |
2023-03-29 | 開始されました | H.C. Wainwright | Buy |
2023-03-24 | 開始されました | RBC Capital Mkts | Outperform |
2022-12-06 | 開始されました | UBS | Buy |
2022-11-02 | 開始されました | Evercore ISI | Outperform |
2022-11-01 | 開始されました | Cowen | Outperform |
2022-10-31 | 開始されました | Guggenheim | Neutral |
2022-06-17 | 開始されました | BMO Capital Markets | Outperform |
2022-03-15 | 開始されました | Barclays | Overweight |
2022-01-31 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2022-01-06 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2021-12-21 | 開始されました | Piper Sandler | Overweight |
2021-05-18 | 開始されました | BTIG Research | Buy |
2020-07-01 | 開始されました | JP Morgan | Overweight |
2020-07-01 | 開始されました | Jefferies | Buy |
2020-06-30 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Legend Biotech Corp Adr (LEGN) 最新ニュース
Legend Biotech stock hits 52-week low at $38.59 amid market shifts - Investing.com
Legend Biotech's SWOT analysis: stock shows promise amid CAR-T therapy growth - Investing.com India
Legend Biotech shares steady with Overweight rating as Cantor raises target on Carvykti potential - Investing.com India
Legend Biotech shares steady with Overweight rating as Cantor raises target on Carvykti potential By Investing.com - Investing.com South Africa
Earnings call: Legend Biotech sees robust growth in CARVYKTI sales - Investing.com
Legend Biotech (LEGN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - MSN
Legend Biotech (LEGN) Reports Q3 Earnings: What Key Metrics Have to Say - Yahoo Finance
T-Cell Lymphoma Pipeline Insight Analysis Report 2024 - GlobeNewswire Inc.
Legend Biotech's SWOT analysis: carvykti success drives stock outlook - Investing.com
Gilead Science to Report Q3 Earnings: What's in the Cards? - Yahoo Finance
Legend Biotech appoints new President for CARVYKTI - Investing.com
Legend Biotech Corp ADR (NASDAQ:LEGN) Stock Is up 15.91% From Its Low, This Stock Is Just Warming Up - Stocks Register
Wall Street Analysts Believe Legend Biotech (LEGN) Could Rally 90.83%: Here's is How to Trade - Yahoo Finance
Adma Biologics Inc (ADMA) Should Be Considered For The Next Few Weeks - Stocks Register
Legend Biotech shares hold Buy rating, $91 target despite Q3 CARVYKTI sales - Investing.com India
Legend Biotech shares hold as Barclays maintains $94 target - Investing.com India
Company’s Banking Stock: Dissecting a -18.35% Quarterly Revenue Decline Amid Growth - The InvestChronicle
Redburn Atlantic initates Legend Biotech Corp ADR (LEGN) rating to a Buy - Knox Daily
Li Auto Inc ADR (LI) rating downgrades by Macquarie - Knox Daily
Recent Insider Activity Suggests Potential Gains for Enovix Corporation (ENVX) - Knox Daily
BMO maintains steady target on Legend Biotech on strong sales - Investing.com
BMO maintains steady target on Legend Biotech on strong sales By Investing.com - Investing.com South Africa
Stock Performance Spotlight: Legend Biotech Corp ADR (LEGN) Ends the Day at 49.68, Down by -0.64 - The Dwinnex
Legend Biotech Corp ADR’s results are impressive - US Post News
UnitedHealth, NVIDIA lead Tuesday's afternoon market cap stock movers By Investing.com - Investing.com UK
Legend Biotech maintains shares price target on steady Q3 growth - Investing.com
Legend Biotech Corp ADR’s Mixed Bag: Down -8.63% in 6 Months, Down 1.03% in 30 Days - The InvestChronicle
Market Insights: Legend Biotech Corp ADR (LEGN)’s Notable Gain of 1.62, Closing at 48.84 - The Dwinnex
Legend Biotech shares hold strong with positive outlook on robust Carvykti sales - Investing.com
Legend Biotech Corp ADR (LEGN) is a good investment, but the stock may be overvalued - US Post News
Redburn sees growth potential for Legend Biotech stock on Carvykti demand - Investing.com
Does Legend Biotech Corp ADR (LEGN) offer a good opportunity for investors? - SETE News
Legend Biotech stock maintains positive outlook with new Philadelphia R&D facility - Investing.com
Upward Trajectory: Legend Biotech Corp ADR (LEGN) Posts a Gaine, Closing at 48.68 - The Dwinnex
Legend Biotech Corp ADR (LEGN) stock analysis: A simple moving average approach - US Post News
You might want to take a look at Legend Biotech Corp ADR (LEGN) now - SETE News
Legend Biotech shares maintain Buy rating from H.C. Wainwright By Investing.com - Investing.com South Africa
BMO maintains Outperform rating on Legend Biotech shares on Carvykti data - Investing.com India
Legend Biotech shares maintain Buy rating from H.C. Wainwright - Investing.com India
Legend Biotech's SWOT analysis: carvykti success drives stock potential - Investing.com
Legend Biotech reiterates stock target, overweight on Phase III data - Investing.com
Legend Biotech stock poised for growth with compelling data on Carvykti - Investing.com
Legend Biotech Corp ADR (LEGN) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
Can you now get a good deal on Legend Biotech Corp ADR’s shares? - US Post News
There is no doubt that Legend Biotech Corp ADR (LEGN) ticks all the boxes. - SETE News
Closing Bell Recap: Legend Biotech Corp ADR (LEGN) Ends at 45.92, Reflecting a -5.38 Downturn - The Dwinnex
Analytical Lens: Exploring Legend Biotech Corp ADR (LEGN)’s Financial Story Through Ratios - The Dwinnex
What was Legend Biotech Corp ADR (LEGN)’s performance in the last session? - US Post News
European Investors Can Invest in the Future of U.S. Healthcare With This ETF - Trackinsight
Legend Biotech Corp Adr (LEGN) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):